# Solve Therapeutics funding rounds and investors

As of 14 Oct 2026, Solve Therapeutics has raised $120M across 1 verified round on record; latest: $120 million funding round led by Yosemite, announced 17 Nov 2025.

Novel antibody-drug conjugates (ADCs) for cancer treatment targeted at solid tumors and optimized for payload delivery using proprietary technology.

Website: https://solvetx.com  
Headquarters: San Diego, CA  
Page: https://fireround.dev/companies/solvetx.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-11-17 | Funding round | $120 million | Yosemite | Abingworth, Alexandria Venture Investments, Ally Bridge Group, AyurMaya Capital Management, Balyasny Asset Management, B Capital, DC Global Ventures, General Atlantic, Merck & Co, Surveyor Capital (a Citadel company), SymBiosis | [businesswire.com](https://www.businesswire.com/news/home/20251117481427/en/Solve-Therapeutics-Raises-%24120-Million-to-Develop-Best-in-Class-ADCs-for-Solid-Tumors) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.